Extremely oblique sclerotomy incision reduces wound leakage in vitrectomy

Article

Extremely oblique sclerotomy incision (OSI) has a self-sealing effect on sclerotomy wound leakages.

Extremely oblique sclerotomy incision (OSI) has a self-sealing effect on sclerotomy wound leakages, says an investigation published in Retina.

The nested case-control study, led by Dr Albert L. Lin, Department of Ophthalmology, Cullen Eye Institute, Houston, Texas, USA, involved 48 patients with wound leaks and 171 control patients without leaks. Patients received either a conventional sclerotomy incision of 45°, changed to 90° midincision, or an OSI at 10°, changed to 30° midincision.

Age, gender, laterality, duration of surgery, preoperative diagnosis, vitrectomy history, sclerotomy incision and primary surgeon were the risk factors investigated.

After using multivariate logistic regression analysis it was discovered that OSI, macular preoperative diagnosis, surgical duration, no previous vitrectomy, and female gender were the protective factors for wound leakage. Using OSI compared to a standard sclerotomy incision reduces the chance of wound leakage.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.